+49 8141 150 55 0


Since February 2019, Scintomics GmbH and its subsidiaries have an exclusive sublicense on European Patent EP 1 289 571 B1 which is in force in Germany, Great Britain, France, Italy and Spain. This Exclusive License also comprises Australian Patent AU2001/277488B2

This sublicense covers DOTAGA-conjugated bioactive compounds and their radiometalated products that bind to the following target structures:

PSMA (also known as glutamate carboxypeptidase II)
Somatostatin receptors
Chemokine receptors (i.e. CXCR4)
Bombesin receptors (BB1-BB3)
Folate receptors
Heat shock proteins
Fibroblast-activating protein (FAP)

Subscribe to our newsletter

Get all the latest information on events, sales & offers.
Sign up for our newsletter:

    Our mission

    Our mission is to develop new and powerful agents for cancer imaging and therapy that improve treatment decisions and the clinical management of cancer patients.